TheraRadar
Landscape / Urology
Data updated: Nov 12, 2026

Overactive Bladder Clinical Trial Landscape

Overactive Bladder is being studied across 260 clinical trials registered since 2008, with 33 programs currently active. The competitive pipeline includes 5 active Phase 3 trials, 9 active Phase 2 trials, and 2 active Phase 1 trials.

Trial activity

33 active / 260 total since 2008
Active by phase 5 Ph3 / 67 9 Ph2 / 50 2 Ph1 / 42 17 Ph4 / 101

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed
Vensica Therapeutics Ltd. 1 0 0
Trigone Pharma Ltd. 1 0 0
NinaMED Pty Ltd 1 0 0
Astellas 0 18 2
AbbVie 0 16 1
Pfizer 0 10 0
Bayer 0 7 0
Urovant Sciences GmbH 0 6 0
Jeil Pharmaceutical Co., Ltd. 0 5 0
Merck 0 3 1
Ipsen 0 0 3
Velicept Therapeutics, Inc. 0 3 0

All 12 active Overactive Bladder sponsors

Unlock the remaining 4 sponsors with active / completed / failed counts — sortable and exportable.

Unlock with Pro

How the field has grown

New-trial starts peaked in 2016 (20 registered); 2025 saw 5. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (23 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016
20
2017
11
2018
15
2019
11
2020
15
2021
9
2022
10
2023
7
2024
9
2025
5
2026
12

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (4)
243
2017 (1)
160
2018 (4)
292
2019 (4)
207
2020 (2)
180
2021 (2)
63
2022 (2)
329
2023 (1)
66
2024 (1)
236
2025 (0)
0
2026 (2)
175

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT05878951 ACTIVE NOT RECRUITING
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Northwestern University n=66
NCT07429734 NOT YET RECRUITING
Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women
Mansoura University n=60
NCT03952299 RECRUITING
Oxybutynin for Post-surgical Bladder Pain and Urgency
University of California, Davis n=100
NCT06551246 RECRUITING
Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)
University of Aarhus n=236
NCT07780786 NOT YET RECRUITING
Non-invasive Saphenous Nerve Stimulation Therapy for Overactive Bladder
NinaMED Pty Ltd n=290
NCT04171531 COMPLETED
Sling vs Botox for Mixed Incontinence
NICHD Pelvic Floor Disorders Network n=150
NCT04641975 TERMINATED
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
Astellas Pharma Global Development, Inc. n=26
NCT01972841 COMPLETED
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
Astellas Pharma Europe B.V. n=3,527
NCT02045862 COMPLETED
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
Astellas Pharma Europe B.V. n=1,829
NCT03149809 COMPLETED
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
VA Office of Research and Development n=77
NCT05390970 COMPLETED
Platelet-Rich Plasma for Stress Urinary Incontinence
Annah J. Vollstedt n=50
NCT04103450 COMPLETED
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
Urovant Sciences GmbH n=276
NCT03902080 COMPLETED
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Urovant Sciences GmbH n=1,105
NCT05282069 COMPLETED
A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder
Dong-A ST Co., Ltd. n=607
NCT04084340 COMPLETED
tDCS and Female Urinary Incontinence
Universidade Federal do Piauí n=60
NCT04048356 COMPLETED
Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures
University of New Mexico n=137
NCT00782769 COMPLETED
A Safety Extension Study of DR-OXY-301
Duramed Research n=240
NCT02097121 TERMINATED
OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)
Allergan n=56
NCT02660359 TERMINATED
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2
Ipsen n=258
NCT02660138 TERMINATED
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
Ipsen n=227
NCT04026880 WITHDRAWN
Testosterone Effects on Pelvic Floor Muscles
Brigham and Women's Hospital
NCT02352103 COMPLETED
Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery
Henry Ford Health System n=120
NCT04917315 COMPLETED
To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder
Jeil Pharmaceutical Co., Ltd. n=210
NCT03583372 COMPLETED
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
Urovant Sciences GmbH n=506
NCT03492281 COMPLETED
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
Urovant Sciences GmbH n=1,530
NCT04534491 COMPLETED
Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.
Bayer n=855
NCT01959347 COMPLETED
Combined Treatment for Mixed Incontinence
NICHD Pelvic Floor Disorders Network n=480
NCT01852058 COMPLETED
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
Allergan n=95
NCT01786967 COMPLETED
Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)
University of North Carolina, Chapel Hill n=61
NCT01852045 COMPLETED
Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients
Allergan n=114
NCT02529865 COMPLETED
Clinical Trial of Autologous Adipose Derived Regenerative Cells for the Treatment of Male Stress Urinary Incontinence
Nagoya University n=45
NCT03532789 COMPLETED
Herbal Patch for Overactive Bladder
En Chu Kong Hospital n=66
NCT02614482 COMPLETED
Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.
Stéphane Bolduc n=26
NCT02327936 COMPLETED
Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children
Stéphane Bolduc n=62
NCT03575702 COMPLETED
Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.
R-Pharm n=300
NCT00876447 COMPLETED
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
Allergan n=397
NCT00915525 COMPLETED
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Allergan n=829
NCT01600716 COMPLETED
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Allergan n=144
NCT01767519 COMPLETED
A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
Allergan n=356
NCT03438422 COMPLETED
Effect of Pollen Extract on Urinary Incontinence
Dr. Santiago Palacios n=160
NCT01220726 COMPLETED
Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
Weill Medical College of Cornell University n=30
NCT02468830 COMPLETED
Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder
CHU de Quebec-Universite Laval n=58
NCT01502956 COMPLETED
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
NICHD Pelvic Floor Disorders Network n=386
NCT01166438 COMPLETED
Anticholinergic vs. Botox Comparison Study
NICHD Pelvic Floor Disorders Network n=249
NCT02476175 COMPLETED
Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder
CHU de Quebec-Universite Laval n=35
NCT02805452 TERMINATED
Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer
Center Eugene Marquis n=4
NCT01520948 COMPLETED
Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease
Atlanta VA Medical Center n=53
NCT01724242 WITHDRAWN
Vaginal DHEA for Women After Breast Cancer
Hadassah Medical Organization
NCT02129816 TERMINATED
Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder
University of Zurich n=9
NCT01175382 COMPLETED
Combined Behavioral and Drug Treatment of Overactive Bladder in Men
University of Alabama at Birmingham n=204
NCT03059134 COMPLETED
Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
Buddhist Tzu Chi General Hospital n=168
NCT02485067 COMPLETED
Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB
SK Chemicals Co., Ltd. n=384
NCT00685113 COMPLETED
A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder
Duramed Research n=1,104
NCT02143570 COMPLETED
Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women
Universidad de Valparaiso n=80
NCT00667095 TERMINATED
Over Active Bladder Instillation Study - Botox
Mayo Clinic n=25
NCT00909181 COMPLETED
Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
Antares Pharma Inc. n=626
NCT01384084 COMPLETED
Pelvic Organ Prolapse Repair Plus Mini-Sling Versus Pelvic Organ Prolapse Repair Alone
University Of Perugia n=50
NCT01067261 COMPLETED
Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Preservation and Restoration of Urinary Continence and Erectile Function and in the Treatment of Erectile Dysfunction and Urinary Incontinence in Conjunction With Nerve Sparing Radical Prostatectomy
Copenhagen University Hospital at Herlev n=68
NCT01366066 TERMINATED
Transcutaneous Mechanical Nerve Stimulation in the Treatment of Incontinence
Copenhagen University Hospital at Herlev n=4
NCT00910845 COMPLETED
Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Allergan n=557
NCT00910520 COMPLETED
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Allergan n=548
NCT01464372 TERMINATED
Electromagnetic Stimulation for the Treatment of Urge Urinary Incontinence and Overactive Bladder
EMKinetics, Inc n=130
NCT01048541 COMPLETED
Bladder Scan of Residual Urine With New Catheter
Coloplast A/S n=37
NCT00695058 WITHDRAWN
Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Incontinence
Copenhagen University Hospital at Herlev
NCT01512004 COMPLETED
Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder
Lee's Pharmaceutical Limited n=324
NCT00611026 COMPLETED
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.
Pfizer n=2,417
NCT00658684 COMPLETED
Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.
Pfizer n=153

Full Overactive Bladder Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only